68 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
on representations made by Remainco, Spinco, Parent, and their respective representatives, and not by independent review, and shall function only as an expert
425
szbfx4i6d2qj1yn1bz
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
jh7cqf
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
wlkt3hsgkp7brqn
29 Jul 21
Ligand Reports Second Quarter 2021 Financial Results
4:04pm
8-K
EX-2.1
igg9daawxr5svp9joi5w
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.4
x4pt78
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm